RxDoctor Payments Data

Jenna Goldstein, PA

Physician Assistant · Smithtown, NYNPI 1134813249

Payments from drug & device makers

$8,244in general payments, 2019–2025

Across 300 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Xeris Pharmaceuticals, Inc.$942
  • Bayer$718
  • Amgen$654
  • Novo Nordisk$499
  • Insulet Corporation$369
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$8,19999%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,244 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$1,860
Medicare patients
13
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$193,618
JardianceEmpagliflozin86$118,989
TradjentaLinagliptin45$58,187
MounjaroTirzepatide30$47,845
TrulicityDulaglutide26$46,029
FarxigaDapagliflozin Propanediol34$43,066
JanuviaSitagliptin Phosphate31$35,485
ProliaDenosumab16$27,614
Tresiba Flextouch U-100Insulin Degludec34$25,397
Tresiba Flextouch U-200Insulin Degludec13$11,245
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,535
Novolog FlexpenInsulin Aspart29$7,986
NovologInsulin Aspart23$7,926
Nano 2nd Gen Pen NeedlePen Needle, Diabetic55$6,195
SynthroidLevothyroxine Sodium50$4,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$499$201,543134 claims
Boehringer IngelheimJardiance, Tradjenta$345$177,176131 claims
Lilly USA, LLCMounjaro, Trulicity$1,097$93,87456 claims
AstraZenecaFarxiga$124$43,06634 claims
AmgenProlia$654$27,61416 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$346$3,175232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →